Who owns Endo Pharmaceuticals?

Key details on Endo Pharmaceuticals (Ticker: ENDP)

Who owns Endo Pharmaceuticals?

Is ENDP a good stock to own? Find out who bought Endo Pharmaceuticals, who sold Endo Pharmaceuticals (ENDP) stock, and who holds a large position in Endo Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
Schroder Investment Management 27.47M $1.25B Sept. 30, 2013
BNP PARIBAS ARBITRAGE, SNC 15.50M $2.46B Sept. 30, 2013
Capital Research Global Investors^ 14.07M $949.38M Dec. 31, 2013
Janus Capital Management 10.19M $687.45M Dec. 31, 2013
Blue Ridge Capital 8.00M $539.68M Dec. 31, 2013
Vanguard 6.81M $459.17M Dec. 31, 2013
D. E. Shaw & Co 5.82M $180.25M June 30, 2012
FMR 5.73M $386.67M Dec. 31, 2013
MORGAN STANLEY 5.64M $380.49M Dec. 31, 2013
Maverick Capital 5.09M $161.40M Sept. 30, 2012
BlackRock Fund Advisors 4.74M $319.71M Dec. 31, 2013
Herndon Capital Management 4.63M $210.20M Sept. 30, 2013
Lone Pine Capital 4.34M $292.78M Dec. 31, 2013
STATE STREET CORPORATION 3.83M $100.62M Dec. 31, 2013
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3.64M $245.25M Dec. 31, 2013
Levin Capital Strategies 3.32M $102.03M March 31, 2013
VIKING GLOBAL INVESTORS 3.24M $147.04M Sept. 30, 2013
GOLDMAN SACHS 3.22M $217.51M Dec. 31, 2013
BlackRock Institutional Trust Company, N.A. 3.14M $211.99M Dec. 31, 2013
Visium Asset Management 2.79M $126.59M Sept. 30, 2013
LSV Asset Management 2.77M $126.02M Sept. 30, 2013
S.A.C. Capital Advisors 2.67M $82.25M March 31, 2013
Bank of America Corporation 2.49M $113.10M Sept. 30, 2013
Epoch Investment Partners 2.33M $105.74M Sept. 30, 2013
Name : Steadfast Capital Management 2.15M $144.96M Dec. 31, 2013
Inves 2.11M $142.35M Dec. 31, 2013
Barclays 2.00M $73.76M June 30, 2013
Hussman Econometrics Advisors 1.91M $59.30M June 30, 2012
SEIZERT CAPITAL PARTNERS 1.72M $115.82M Dec. 31, 2013
Antipodean Advisors 1.62M $109.02M Dec. 31, 2013
Robeco Investment Management 1.57M $57.62M June 30, 2013
Falcon Edge Capital 1.54M $104.16M Dec. 31, 2013

Who sold Endo Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
HARRIS FINANCIAL Sept. 30, 2011 2.65M $74.04M
Samlyn Capital Sept. 30, 2011 2.00M $55.98M
Royce & Associates March 31, 2011 5.96M $227.36M
OrbiMed Advisors Dec. 31, 2010 1.67M $59.72M
Greenlight Capital March 31, 2003 2.10M $28.27M